share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Jan 26 12:54
Summary by Moomoo AI
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private placement and, along with the ADSs underlying the warrants, have not been registered under the Securities Act, thus limiting their sale to certain conditions. The event took place on January 26, 2024, and is part of RedHill's ongoing efforts to fund its operations and development programs, including those for gastrointestinal and infectious diseases.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more